SI-Bone: Durable Growth, Conservative Outlook, and Discounted Valuation Support Buy Rating

SI-Bone, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Caitlin Roberts from Canaccord Genuity maintained a Buy rating on the stock and has a $27.00 price target.

Caitlin Roberts has given his Buy rating due to a combination of factors, including SI-Bone’s solid Q4 performance and evidence of durable growth in its core business. The company delivered revenue and earnings results ahead of expectations, driven by double-digit expansion in active physicians, rising procedure volumes, and consistent gains in sales territory productivity, all of which point to ongoing penetration of its target surgeon base.

Roberts’s rating is based on the view that SI-Bone is building a scalable growth platform supported by new products, international expansion, and a strategically important partnership with Smith & Nephew. She also notes that management’s FY26 revenue outlook appears conservative relative to the potential contribution from recent launches and the distribution deal, while the shares trade at a discount to faster-growing medtech peers, creating an attractive risk‑reward profile for investors.

In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $23.00 price target.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SIBN in relation to earlier this year.